Lawsuit filed for Investors who lost money with shares of Merck & Co., Inc. (NYSE: MRK)

An investor, who purchased shares of Merck & Co., Inc. (NYSE: MRK), filed a lawsuit over alleged violations of Federal Securities Laws by Merck & Co., Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Merck & Co., Inc. (NYSE: MRK) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NYSE: MRK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On July 30, 2024, Merck & Co., Inc. (NYSE: MRK) released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck's Chinese distributer. The Company announced that its shipments of Gardasil to China may fall below contracted levels for 2024.

Then, on February 4, 2025, Merck & Co., Inc. (NYSE: MRK) declined its fourth quarter and full year 2025 financial results. Merck & Co., Inc. (NYSE: MRK) also disclosed that it would entirely cease shipments of Gardasil to China "through at least midyear" to facilitate a "rapid reduction of inventory," citing a continued over-inflation of channel inventories as demand in China had "not recovered to the level [the Company] had expected." Merck also announced that it would no longer achieve its long-forecasted $11 billion in sales of Gardasil by 2030.

Shares of Merck & Co., Inc. (NYSE: MRK) declined from $134.63 per share on June 25, 2024, to as low as $81.04 per share on February 18, 2025.

The plaintiff claims that between February 3, 2022 to February 3, 2025, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that they possessed reliable information pertaining to Merck's projected revenue outlook and anticipated growth of Gardasil while also minimizing risk from competition and drug approval development, such as China's approval to shift Gardasil to a 2-dose regimen, that in truth, Merck's optimistic reports of growth, claims of successful consumer activation and education in China, overall ability to drive demand, and efforts to downplay the impact of competition on Gardasil fell short of the reality, and that Merck's ability to push Gardasil in China had materially diminished.

Those who purchased shares of Merck & Co., Inc. (NYSE: MRK) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.